Skip to main content
SpringerLink
Log in

Single-Center Experience Using Selexipag in a Pediatric Population

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Pulmonary arterial hypertension (PAH) is a rare and progressive disorder. Current treatment in the pediatric population includes phosphodiesterase 5 inhibitors (PDE-5i), endothelin receptor antagonists (ERA), and both inhaled and intravenous prostacyclin pathway agonists. As of December 22, 2015 the first oral prostacyclin pathway agonist, selexipag (Uptravi®), was FDA approved in the US. In this case series, we discuss our single-center experience using selexipag in a pediatric population, composed of both patients with idiopathic PAH, and patients with congenital heart disease and PAH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hoeper MM, Bogaard HJ, Condliffe R et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42–D50

    Article  PubMed  Google Scholar 

  2. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351:1655–1665

    Article  CAS  PubMed  Google Scholar 

  3. Farber HW, Miller D, Poms AD et al (2015) Five-year outcomes of patients enrolled in the REVEAL registry. Chest 148:1043–1054

    Article  PubMed  Google Scholar 

  4. Haworth SG, Hislop AA (2009) Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006. Heart 95:312–317

    Article  CAS  PubMed  Google Scholar 

  5. Kitterman N, Poms A, Miller DP et al (2012) Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®. Mayo Clin Proc 87(9):825–834

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kallen AJ, Lederman E, Balaji A et al (2008) Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 29(4):342–349

    Article  PubMed  Google Scholar 

  7. Marr CR, McSweeney JE, Mullen MP, Kulik TJ (2015) Central venous line complications with chronic ambulatory infusion of prostacyclin analogues in pediatric patients with pulmonary arterial hypertension. Pulm Circ 5(2):322–326

    Article  PubMed  PubMed Central  Google Scholar 

  8. Drogalis-Kim D, Jefferies J, Wilmot I, Alejos J (2016) Right sided heart failure and pulmonary hypertension: new insights into disease mechanisms and treatment modalities. Prog Pediatr Cardiol 43:71–80

    Article  Google Scholar 

  9. Sharma K (2016) Selexipag for the treatment of pulmonary arterial hypertension. Expert Rev Respir Med 10(1):1–3

    Article  CAS  PubMed  Google Scholar 

  10. Takatsuki S, Parker DK, Doran AK, Friesen RH, Ivy DD (2013) Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. Pediatr Cardiol 34(4):1006–1012

    Article  PubMed  Google Scholar 

  11. Sitbon O, Channick R, Chin KM et al (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522–2533

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Cardiology, Mattel Children’s Hospital UCLA, 200 UCLA Medical Plaza, Suite 224, Los Angeles, CA, 90095, USA

    Roberto Gallotti, Diana E. Drogalis-Kim, Gary Satou & Juan Alejos

  2. Division of Pulmonary Hypertension, Mattel Children’s Hospital UCLA, Los Angeles, CA, 90095, USA

    Gary Satou & Juan Alejos

Authors
  1. Roberto Gallotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana E. Drogalis-Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary Satou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Alejos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juan Alejos.

Ethics declarations

Conflict of interest

Juan Alejos MD has received a speaker honorarium from Actelion Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gallotti, R., Drogalis-Kim, D.E., Satou, G. et al. Single-Center Experience Using Selexipag in a Pediatric Population. Pediatr Cardiol 38, 1405–1409 (2017). https://doi.org/10.1007/s00246-017-1677-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-017-1677-7

Keywords

Search

Navigation